NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)

The National Institutes of Health (NIH) is seeking applications for the NHLBI SBIR Phase IIB Bridge Awards to accelerate the commercialization of technologies for heart, lung, blood, and sleep disorders and diseases. The goal of this initiative is to assist applicants in pursuing the milestone(s) necessary to advance a product to regulatory approval and commercialization by promoting partnerships between SBIR Phase II awardees and third-party investors and/or strategic partners. • The initiative will support later-stage research and development (referred to as Phase IIB) for promising projects that were previously funded by SBIR or STTR Phase II awards and will require eventual Federal regulatory approval/clearance. • The initiative will give competitive preference and funding priority to applications deemed likely to result in a clinically-relevant commercial product, as indicated by the applicant's ability to secure independent third-party investor funds. • The initiative will utilize the R44 activity code. • The estimated funding for this initiative is $52,500,000, with an award ceiling of $3,500,000. • The application due date is February 26, 2027.